Edgestream Partners L.P. Has $1.47 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Edgestream Partners L.P. lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 74.1% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,052 shares of the biopharmaceutical company’s stock after selling 17,303 shares during the quarter. Edgestream Partners L.P.’s holdings in Alnylam Pharmaceuticals were worth $1,471,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Dimensional Fund Advisors LP lifted its holdings in shares of Alnylam Pharmaceuticals by 4.3% during the second quarter. Dimensional Fund Advisors LP now owns 266,206 shares of the biopharmaceutical company’s stock worth $64,702,000 after buying an additional 11,027 shares in the last quarter. Dai ichi Life Insurance Company Ltd bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $262,000. SYM FINANCIAL Corp bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $217,000. DekaBank Deutsche Girozentrale increased its position in shares of Alnylam Pharmaceuticals by 0.4% in the second quarter. DekaBank Deutsche Girozentrale now owns 113,463 shares of the biopharmaceutical company’s stock worth $27,885,000 after purchasing an additional 421 shares during the period. Finally, Meeder Asset Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 1,237.5% in the second quarter. Meeder Asset Management Inc. now owns 321 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 297 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.9 %

Shares of ALNY stock opened at $273.88 on Friday. The business’s 50-day moving average price is $260.11 and its 200-day moving average price is $198.73. The firm has a market capitalization of $34.64 billion, a price-to-earnings ratio of -102.19 and a beta of 0.38. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million during the quarter, compared to analyst estimates of $447.22 million. Alnylam Pharmaceuticals’s revenue was up 107.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.21) earnings per share. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $276,726.02. Following the transaction, the executive vice president now directly owns 14,181 shares of the company’s stock, valued at $3,275,669.19. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CEO Yvonne Greenstreet sold 15,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the business’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $276,726.02. Following the transaction, the executive vice president now owns 14,181 shares in the company, valued at approximately $3,275,669.19. The disclosure for this sale can be found here. Insiders have sold a total of 103,148 shares of company stock valued at $25,658,824 over the last ninety days. 1.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ALNY. Bank of America raised their price target on Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Evercore ISI raised their price target on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 25th. The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the stock from $198.00 to $370.00 in a research report on Friday, August 16th. UBS Group raised their price target on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a “buy” rating in a research report on Friday, June 28th. Finally, JPMorgan Chase & Co. lifted their target price on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research report on Monday, August 26th. Seven equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $279.14.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.